Similar articles

• An immunological method for detection of the carrier of hemophilia B.

  Matsuoka M, Ito M, Takahashi K, Sakuragawa N. Matsuoka M, et al. Thromb Haemost. 1976 Nov 30;36(2):441-50. Thromb Haemost. 1976. PMID: 1036844
• Characterization and experimental use of a monospecific antiserum to factor IX.

  Pechet L, Tiarks CY, Chang CH, Sudhindra RR, Lipworth L. Pechet L, et al. Thromb Haemost. 1979 Feb 15;40(3):455-64. Thromb Haemost. 1979. PMID: 106483
• Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.

  Thompson AR. Thompson AR. J Clin Invest. 1977 May;59(5):900-10. doi: 10.1172/JCI108712. J Clin Invest. 1977. PMID: 856873 Free PMC article.
• Technology evaluation: AAV factor IX gene therapy, Avigen Inc.

  Fabb SA, Dickson JG. Fabb SA, et al. Curr Opin Mol Ther. 2000 Oct;2(5):601-6. Curr Opin Mol Ther. 2000. PMID: 11249763 Review.
• Antibodies to factor IX.

  Warrier I. Warrier I. Haematologica. 2000 Oct;85(10 Suppl):31-3; discussion 33-4. Haematologica. 2000. PMID: 11187867 Review. No abstract available.